MedX Health Corp.

lockPrivate Group

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™,...

people10 Members       (0)

Corporate Profile
Group Admins:
  • Thumb 8020 monitor 200200 2
  • Thumb no photo
  • Thumb no photo
Request Membership


MedX Health Corp.

lockPrivateGroup

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAs......

people10 Members       (0)

Thumb 8020 monitor 200200 2

8020 Admin

6 days ago

8020 Admin posted a press release MedX Receives Major SIAScopeTM Order for Launch of its DermSecureTM Telemedicine Platform in Brazil in MEDX HEALTH CORP.

MISSISSAUGA, ON


MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has received an order for 500 SIAScopeTM units for deployment on its DermSecureTM telemedicine platform from its exclusive Brazilian distributor, representing the single largest order in the Company’s history.


“This order reflects the impact our SIAScopyTM on DermSecureTM platform can have in redefining patient care and shows that MedX’s rapid skin assessment technology is scalable and is receiving strong demand in the Brazilian market,” commented Scott Spearn, CEO of MedX. “MedX will benefit from a “Software as a Service” revenue model with the initial sale of the SIAScopeTM units and then generating recurring revenue as the devices are deployed by mid-2020 on the DermSecure TM platform and patients are scanned in Brazil.”


"There is a significant opportunity for MedX’s rapid skin assessment technology in Brazil, as skin cancer is the most common type of cancer in Brazil,” stated Fabio Camata Candello, CEO of MedX Brasil. “Over a hundred thousand new cases of skin cancer were recorded in Brazil between 2016 and 2017 according to the Brazilian Cancer Institute, and almost 6,000 were classified as melanoma, an aggressive form of the disease that can spread to other parts of the body. A recent study shows that Brazilian melanoma patients experienced a lower survival rate than the current worldwide average. The high prevalence of advanced cases reinforces the importance of local strategies to diagnose melanomas in the early stages, and to treat it definitively. “MedX’s SIAScopyTM on DermSecureTM telemedicine platform and advanced SIAscopy TM imaging technology is a perfect solution for early detection," further noted Mr. Candello.


“MedX Brasil has been premarketing MedX’s technology at trade shows in Brazil and through our channel partner One Way Diagnostica. These efforts have shown strong demand for SIAScopyTM on DermSecureTM and we are starting to build inventory to be able to deploy the units as soon as possible once regulatory approval is granted. We have been working closely with ANVISA, the Brazilian regulatory authority, and expect regulatory approval shortly,” stated Mr. Candello.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its SIAScopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


About MedX Brasil


MedX Brasil is an independent licensee incorporated in Brazil, formed during 2019 to become the exclusive distributor of MedX Canada’s SIAscopy TM on DermSecure TM platform in Brazil. MedX Brasil has established a partnership with Oneway Diagnostics a specialist sales team in the Dermatology market in Brazil. MedX Brasil is responsible for marketing, educating, trade shows, financing activities to support the sales team at Oneway Diagnostics. https://www.medxbrasil.com.br/


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.




Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229



!
Thumb 8020 monitor 200200 2

8020 Admin

2 months ago

8020 Admin posted a press release MedX Health Corp. announces Third Quarter 2019 Results in MEDX HEALTH CORP.

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three and nine-months ended September 30, 2019, which are also available on SEDAR (www.sedar.com).


The Company reported revenue of $234,977 for the three months ended September 30, 2019, compared with revenue of $180,404 for the three months ended September 30, 2018. Revenues from the Company's therapeutic laser line of $177,437 were 41% higher than in the prior year. SIAscopy™ revenues of $57,541 also showed improvement over the 2018 three-month period. The Company reported a loss for the three months ended September 30, 2019 of $577,648 or $0.00 per share compared with a loss of $919,935, or $0.01 per share for the three months ended September 30, 2018.


The Company reported revenue of $678,886 for the nine months ended September 30, 2019, compared with revenue of $812,233 for the nine months ended September 30, 2018. Revenues from the Company’s therapeutic laser line of $574,070 were up 13% for the nine-month period, while SIAscopy™ revenues were lower than the prior year. The Company reported a loss for the nine months ended September 30, 2019 of $2,086,892 or $0.01 per share compared with a loss of $3,171,333, or $0.02 per share for the nine months ended September 30, 2018.


“We experienced an increase in our SIAscopy™ product sales in Q3, a positive sign, with our Brazilian distribution partners participating in industry conferences and building the awareness level and interest in our DermSecure™ telemedicine platform by local dermatologists, as we get closer to regulatory approval in that country,” noted Scott Spearn, CEO of MedX. “We expect to see further interest and increased revenue from the platform as we move into 2020, as the market realizes the benefits of our technology and how we can be a leader in shortening wait times, saving lives and lowering costs to the health care system. In addition, sales from our therapeutic laser products were solid again this quarter, up 41% over last year in Q3, and now 13% higher on a year-to-date basis.”


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.


View source version on businesswire.com: https://www.businesswire.com/news/home/20191127005183/en/



Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229


!
Thumb 8020 monitor 200200 2

8020 Admin

3 months ago

8020 Admin posted a press release MedX Health Corp. Announces Non-Brokered Private Placement in MEDX HEALTH CORP.


NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES


MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it has filed for Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 25,000,000 units at $0.12 per unit (“Unit”), to raise up to $3,000,000. Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. Closing of the Placement, which will take place in tranches, will be subject to receipt of subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. Qualified Agents may receive commissions in respect of subscriptions introduced by them by way of cash equal to 8% of funds so introduced, and issuance of agent’s warrants (“Agent’s Warrant(s)”) equal in number to 8% of the number of units so subscribed for. Each Agent’s Warrant, which is non-transferable, will be exercisable to acquire one Unit at $0.12 per Unit, at any time during the period of two years following the Closing.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.


View source version on businesswire.com: https://www.businesswire.com/news/home/20191101005631/en/



Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229


!
Thumb 8020 media relations

Media Relations posted an update in MEDX HEALTH CORP.

9 months ago

Mike Druhan on the competitive advantages of MedX's (TSXV: MDX) skin cancer diagnosis technology

MedX Health Corp.

lockPrivate Group

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™,...

people10 Members       (0)

Corporate Profile
Group Admins:
  • Thumb 8020 monitor 200200 2
  • Thumb no photo
  • Thumb no photo
Request Membership


MedX Health Corp.

lockPrivateGroup

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAs......

people10 Members       (0)

Thumb 8020 monitor 200200 2

8020 Admin

6 days ago

8020 Admin posted a press release MedX Receives Major SIAScopeTM Order for Launch of its DermSecureTM Telemedicine Platform in Brazil in MEDX HEALTH CORP.

MISSISSAUGA, ON


MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has received an order for 500 SIAScopeTM units for deployment on its DermSecureTM telemedicine platform from its exclusive Brazilian distributor, representing the single largest order in the Company’s history.


“This order reflects the impact our SIAScopyTM on DermSecureTM platform can have in redefining patient care and shows that MedX’s rapid skin assessment technology is scalable and is receiving strong demand in the Brazilian market,” commented Scott Spearn, CEO of MedX. “MedX will benefit from a “Software as a Service” revenue model with the initial sale of the SIAScopeTM units and then generating recurring revenue as the devices are deployed by mid-2020 on the DermSecure TM platform and patients are scanned in Brazil.”


"There is a significant opportunity for MedX’s rapid skin assessment technology in Brazil, as skin cancer is the most common type of cancer in Brazil,” stated Fabio Camata Candello, CEO of MedX Brasil. “Over a hundred thousand new cases of skin cancer were recorded in Brazil between 2016 and 2017 according to the Brazilian Cancer Institute, and almost 6,000 were classified as melanoma, an aggressive form of the disease that can spread to other parts of the body. A recent study shows that Brazilian melanoma patients experienced a lower survival rate than the current worldwide average. The high prevalence of advanced cases reinforces the importance of local strategies to diagnose melanomas in the early stages, and to treat it definitively. “MedX’s SIAScopyTM on DermSecureTM telemedicine platform and advanced SIAscopy TM imaging technology is a perfect solution for early detection," further noted Mr. Candello.


“MedX Brasil has been premarketing MedX’s technology at trade shows in Brazil and through our channel partner One Way Diagnostica. These efforts have shown strong demand for SIAScopyTM on DermSecureTM and we are starting to build inventory to be able to deploy the units as soon as possible once regulatory approval is granted. We have been working closely with ANVISA, the Brazilian regulatory authority, and expect regulatory approval shortly,” stated Mr. Candello.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its SIAScopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


About MedX Brasil


MedX Brasil is an independent licensee incorporated in Brazil, formed during 2019 to become the exclusive distributor of MedX Canada’s SIAscopy TM on DermSecure TM platform in Brazil. MedX Brasil has established a partnership with Oneway Diagnostics a specialist sales team in the Dermatology market in Brazil. MedX Brasil is responsible for marketing, educating, trade shows, financing activities to support the sales team at Oneway Diagnostics. https://www.medxbrasil.com.br/


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.




Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229



!
Thumb 8020 monitor 200200 2

8020 Admin

2 months ago

8020 Admin posted a press release MedX Health Corp. announces Third Quarter 2019 Results in MEDX HEALTH CORP.

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three and nine-months ended September 30, 2019, which are also available on SEDAR (www.sedar.com).


The Company reported revenue of $234,977 for the three months ended September 30, 2019, compared with revenue of $180,404 for the three months ended September 30, 2018. Revenues from the Company's therapeutic laser line of $177,437 were 41% higher than in the prior year. SIAscopy™ revenues of $57,541 also showed improvement over the 2018 three-month period. The Company reported a loss for the three months ended September 30, 2019 of $577,648 or $0.00 per share compared with a loss of $919,935, or $0.01 per share for the three months ended September 30, 2018.


The Company reported revenue of $678,886 for the nine months ended September 30, 2019, compared with revenue of $812,233 for the nine months ended September 30, 2018. Revenues from the Company’s therapeutic laser line of $574,070 were up 13% for the nine-month period, while SIAscopy™ revenues were lower than the prior year. The Company reported a loss for the nine months ended September 30, 2019 of $2,086,892 or $0.01 per share compared with a loss of $3,171,333, or $0.02 per share for the nine months ended September 30, 2018.


“We experienced an increase in our SIAscopy™ product sales in Q3, a positive sign, with our Brazilian distribution partners participating in industry conferences and building the awareness level and interest in our DermSecure™ telemedicine platform by local dermatologists, as we get closer to regulatory approval in that country,” noted Scott Spearn, CEO of MedX. “We expect to see further interest and increased revenue from the platform as we move into 2020, as the market realizes the benefits of our technology and how we can be a leader in shortening wait times, saving lives and lowering costs to the health care system. In addition, sales from our therapeutic laser products were solid again this quarter, up 41% over last year in Q3, and now 13% higher on a year-to-date basis.”


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.


View source version on businesswire.com: https://www.businesswire.com/news/home/20191127005183/en/



Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229


!
Thumb 8020 monitor 200200 2

8020 Admin

3 months ago

8020 Admin posted a press release MedX Health Corp. Announces Non-Brokered Private Placement in MEDX HEALTH CORP.


NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES


MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it has filed for Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 25,000,000 units at $0.12 per unit (“Unit”), to raise up to $3,000,000. Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. Closing of the Placement, which will take place in tranches, will be subject to receipt of subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. Qualified Agents may receive commissions in respect of subscriptions introduced by them by way of cash equal to 8% of funds so introduced, and issuance of agent’s warrants (“Agent’s Warrant(s)”) equal in number to 8% of the number of units so subscribed for. Each Agent’s Warrant, which is non-transferable, will be exercisable to acquire one Unit at $0.12 per Unit, at any time during the period of two years following the Closing.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.


View source version on businesswire.com: https://www.businesswire.com/news/home/20191101005631/en/



Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229


!
Thumb 8020 media relations

Media Relations posted an update in MEDX HEALTH CORP.

9 months ago

Mike Druhan on the competitive advantages of MedX's (TSXV: MDX) skin cancer diagnosis technology